Skip to main

A research-curriculum digest of the tesamorelin literature — the GHRH-analogue peptide laid out module by module, with the visceral-fat trials, the regulatory scope, and the honest gaps charted like a syllabus.

How do these 2 medicines compare?

Tesamorelin vs Sermorelin: Which Differences Matter?

Both prompt growth hormone, yet only one has large human studies and an approved use. Their make-up also differs.

What is the main difference between these medicines?

Both medicines copy a message the growth gland can read, though sermorelin copies a shorter part than tesamorelin. The gland answers by sending growth hormone into the blood; neither medicine is growth hormone itself.

Tesamorelin has an added part that slows breakdown, plus large human studies for one HIV use. Sermorelin starts the same body process but has far less human study, a gap you and your doctor can weigh.

No direct test has shown that either medicine works better. A doctor who knows your health can help you weigh that gap.

How do both drugs start the same body process?

Both medicines attach to cells in the growth gland. That contact prompts timed hormone bursts and raises 1 growth protein made by the liver [1].

Neither medicine gives growth hormone to the body. Each makes the gland send more of the body's own hormone into the blood.

Tesamorelin copies the full message, which has 44 protein parts [1]. It also has an added part that helps the medicine last.

Sermorelin copies only the first 29 parts of that message. Sermorelin lacks the added part found on tesamorelin.

Their length and added part clearly differ. Those facts don't tell you which medicine will work better for one patient.

How do both drugs start the same body process?

Why does tesamorelin resist early breakdown?

The body quickly cuts up the natural growth message. It can also break down sermorelin and other close copies.

Tesamorelin has 1 added part at one end. That part slows the body's cutting action [1][7].

Half the medicine leaves the blood in well under an hour. Yet the rise in a liver-made growth protein lasts through the daily study period [1].

The added part explains why the medicines break down at different rates. It doesn't show which one is right for you.

Which drug has stronger support from human studies?

Tesamorelin has much more proof from human studies. In 2010, the FDA approved one use tied to HIV [5].

Two large late-stage studies, called Phase 3 studies, form much of that record [1]. A liver-fat study, a 2024 test, and a 2026 review added more results [3][12][13].

The review found less deep belly fat after tesamorelin. No study in these sources compared tesamorelin with sermorelin head to head.

The FDA limits tesamorelin to fat changes tied to HIV. All other uses remain off-label [5].

Sermorelin has less human research in the sources used here. The uneven record can't prove which medicine works better.

What are the main differences at a glance?

Tesamorelin copies all 44 protein parts in the natural message. Sermorelin copies only the short opening part and lacks tesamorelin's added shield [1].

That shield helps tesamorelin resist early breakdown [1][7]. It is 1 clear difference in how the medicines are built.

Both prompt timed growth-hormone release and raise a liver-made growth protein. Neither medicine is growth hormone itself [1].

Tesamorelin has large human tests, a review of several tests, and one approved use [5][12]. No direct test can fairly rank the two medicines for you.

The research page explains each body step in order. A doctor can help relate these differences to your health.